Feasibility and Safety of Exercise in Patients With Low-risk Myeloid Cancers and Precursor Conditions
NCT06773871 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36
Last updated 2025-08-19
Summary
Somatic mutations as seen in myeloid malignancies can also be detected in healthy, elderly individuals (clonal hematopoiesis of indeterminate potential, CHIP), in patients with unex-plained cytopenia, that do not fulfill the criteria for myeloid malignancy (clonal cytopenia of un-determined significance, CCUS) It has been shown that these conditions predispose to hema-tological cancer. For patients with CCUS, it has been reported that in a 5-year period up to 50-90 % of the patients will progress to myelodysplastic syndrome (MDS) or acute myeloid leu-kemia (AML), both devastating diseases with poor outcomes, especially for the elderly popula-tion. There is currently no treatment available for patients with CCUS besides supporting agents. Since the somatic mutations can be detected up to 10 years before a diagnosis of MDS, it opens the potential for early intervention.
Physical inactivity is associated with multiple solid cancers, and it has been suggested that exercise can prevent for example certain colon- or breast cancers. Studies in mice have shown that exercise can reduce tumor size and incidence of solid cancers, and different mechanisms have been suggested including increased immune cell infiltration, reduced systemic inflamma-tion, and metabolic changes. The mechanisms of disease progression of pre-leukemia and MDS are complex and probably multifactorial, but recent studies suggest that components such as natural killer cells, adipocytes, and inflammatory substances in the bone marrow mi-croenvironment play a crucial role; factors that exercise may modulate. In addition, recent stud-ies have shown that increased bone marrow adipose tissue (BMAT) may create a microenvi-ronment that supports the expansion of leukemic cells and thus may facilitate disease progres-sion, and earlier studies among healthy, younger individuals have shown that exercise can reduce the amount of BMAT significantly.
Therefore, the investigators hypothesize that exercise may prevent or delay the progression from pre-leukemia to leukemia by altering the microenvironment in the bone marrow.
The purpose with this clinical, pilot trial where patients with the preleukemic condition CCUS or early stage of leukemia (i.e., lower-risk MDS) will undergo an individualized exercise interven-tion, is to investigate:
1. whether an exercise intervention and the trial set-up, are feasible and safe in this cohort,
2. potential mechanisms in leukemogenesis affected by exercise in controlling dis-ease progression,
3. and the effect hereof on quality of life and activities of daily living. The above will inform the decision-making on designing a larger randomized, controlled trial.
Conditions
- Myelodysplastic Syndrome
- Cytopenia
Interventions
- OTHER
-
Exercise
Weekly supervised exercise for 12 weeks followed by 12 weeks of non-supervised exercise
- OTHER
-
Control
Remain usual activity level
Sponsors & Collaborators
-
Rigshospitalet, Denmark
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-03-10
- Primary Completion
- 2027-01-31
- Completion
- 2027-01-31
Countries
- Denmark
Study Locations
More Related Trials
-
Effects of Exercise in Combination With Epoetin Alfa
NCT00577096 ·Status: COMPLETED ·Phase: NA
-
Effects of Zometa and Physical Activity on Bone Density in Women Receiving Chemotherapy for Breast Cancer
NCT00202059 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
NCT00004903 ·Status: UNKNOWN ·Phase: PHASE2
-
Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma
NCT01074060 ·Status: COMPLETED ·Phase: PHASE1
-
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
NCT06928662 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Newly Diagnosed Stage I, Stage II, or Stage III Multiple Myeloma
NCT00526734 ·Status: UNKNOWN ·Phase: PHASE2
-
Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Multiple Myeloma Patients.
NCT01908621 ·Status: COMPLETED ·Phase: PHASE3
-
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Myelogenous Leukemia or Acute Leukemia
NCT00004905 ·Status: COMPLETED ·Phase: PHASE2
-
Study of High-Dose Chemotherapy With Bone Marrow or Stem Cell Transplant for Rare Poor-Prognosis Cancers
NCT00141765 ·Status: COMPLETED ·Phase: PHASE2
-
Physical Activity With or Without Dexamethasone in Reducing Cancer-Related Fatigue in Patients With Locally Advanced, Metastatic, or Recurrent Cancer
NCT03583255 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
NCT01804634 ·Status: RECRUITING ·Phase: PHASE2
-
Mechanical Stimulation in Preventing Bone Density Loss in Patients Undergoing Donor Stem Cell Transplant
NCT01558778 ·Status: WITHDRAWN ·Phase: NA
-
TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma
NCT01039025 ·Status: COMPLETED ·Phase: PHASE2
-
Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts
NCT00968396 ·Status: WITHDRAWN ·Phase: PHASE2
-
Exercise Program (TEAM Me) for the Improvement of Movement and Mobility in Pediatric and Adolescent and Young Adult Patients With Cancer Undergoing a Blood Stem Cell Transplant
NCT04678427 ·Status: RECRUITING ·Phase: NA
-
Early Allogeneic Hematopoietic Cell Transplantation in Treating Patients With Relapsed or Refractory High-Grade Myeloid Neoplasms
NCT02756572 ·Status: COMPLETED ·Phase: PHASE2
-
TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma
NCT03506802 ·Status: WITHDRAWN ·Phase: PHASE1
-
Gemtuzumab in Treating Patients With Myelodysplastic Syndrome
NCT00022321 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
NCT01476137 ·Status: COMPLETED ·Phase: PHASE1
-
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
NCT00536601 ·Status: COMPLETED ·Phase: NA
-
Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis
NCT03426969 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
A Phase I/II Study of Intraperitoneal Paclitaxel in Patients With Metastatic Appendiceal Adenocarcinoma
NCT06207305 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
The Safety and Feasibility of Costal Bone Marrow Aspiration During Thoracic Surgery
NCT05251805 ·Status: TERMINATED ·Phase: NA
-
Chemotherapy Plus Radiation Therapy and Biological Therapy in Treating Patients With Hematologic Cancer
NCT00002553 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Study of Thiopegfilgrastim for Preventing Bone Marrow Suppression in Thoracic Tumor Chemoradiotherapy
NCT07205536 ·Status: RECRUITING ·Phase: PHASE2